The whole point of double blind is so you can analyze results without compromising the study. lol, did you not hear him say that he couldn't know for sure who was getting the drug. He's allowed to look at the anonymized data. Sometimes it surprises me that anyone would invest in a biotech without at least reading an intro 101 paper on clinical trial protocols.